Radioactive main group and rare earth metals for imaging and therapy
TI Kostelnik, C Orvig - Chemical reviews, 2018 - ACS Publications
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature
T Günther, G Tulipano, P Dournaud, C Bousquet… - Pharmacological …, 2018 - Elsevier
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
WP Fendler, KM Pabst, L Kessler, P Fragoso Costa… - Clinical Cancer …, 2022 - AACR
Purpose: We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in
patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental …
patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Experimental …
Somatostatin receptor antagonists for imaging and therapy
M Fani, GP Nicolas, D Wild - Journal of nuclear medicine, 2017 - Soc Nuclear Med
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have
been used for more than 20 y. An important improvement in recent years was the …
been used for more than 20 y. An important improvement in recent years was the …
[HTML][HTML] Somatostatin receptor PET ligands-the next generation for clinical practice
Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
[HTML][HTML] Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs
Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …
personalize patient treatment. In nuclear medicine, this is achieved by using …
First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms …
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …
Radiolabeled peptides and antibodies in medicine
P Kręcisz, K Czarnecka, L Królicki… - Bioconjugate …, 2020 - ACS Publications
Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …
expanding. This group is very diverse in terms of peptide size. It contains very small …
Radiolabeled somatostatin analogs—a continuously evolving class of radiopharmaceuticals
M Fani, R Mansi, GP Nicolas, D Wild - Cancers, 2022 - mdpi.com
Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …
because these proteins are overexpressed on the cell membranes of different human …
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …